CUPID PEPTIDE COMPANY LIMITEDActive

Company number 08121890Private limited companyIncorporated 2012
⚠ Confirmation statement overdue. It was due on 1 Oct 2026.

Key figures

−£21,458-133.6%
Net assets 2024/25
-30 k-20 k-10 k010 k20 k2019/202020/212021/222022/232023/242024/25

Like most small UK companies, CUPID PEPTIDE COMPANY LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
050 k100 k2019/202020/212021/222022/232023/242024/25
Filed accounts2019/20–2024/25
2020/212021/222022/232023/242024/25
Cash at bank and in hand—7,9292,0513,274385
Total assets57,55671,22569,44169,02569,716
Total liabilities44,53255,97263,64478,21191,174
Net assets / total equity13,02415,2535,797-9,186-21,458
Average number of employees20000

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: CUPID PEPTIDE COMPANY LIMITED

Company

CUPID PEPTIDE COMPANY LIMITED is a private limited company registered with Companies House under company number 08121890. It was incorporated on 28 Jun 2012. Its status is active. The registered office is in Cardiff (CF24). Its nature of business (SIC 2007) is manufacture of basic pharmaceutical products (21100).

Accounts

The latest accounts in the database are for 2024/25 (period ending 30 Jun 2025); the company files small company accounts (filleted). Net assets were −£21,458, down 133.6% on the previous year. Cash at bank and in hand was £385. Total assets were £69,716 and total liabilities £91,174. The company had an average of 0 employees. Figures are available for 6 financial years (2019/20–2024/25).

Control and charges

One person with significant control is registered.

Filing deadlines

The next accounts are due by 31 Mar 2027. The next confirmation statement is due by 1 Oct 2026.